{"id":550608,"date":"2026-03-15T12:30:00","date_gmt":"2026-03-15T11:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=550608"},"modified":"2026-03-15T12:55:28","modified_gmt":"2026-03-15T11:55:28","slug":"biologicos-establecidos-y-novedosos-el-panorama-terapeutico-esta-en-constante-cambio","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/biologicos-establecidos-y-novedosos-el-panorama-terapeutico-esta-en-constante-cambio\/","title":{"rendered":"Biol\u00f3gicos establecidos y novedosos: el panorama terap\u00e9utico est\u00e1 en constante cambio"},"content":{"rendered":"\n<p><strong>Cl\u00ednicamente, la dermatitis at\u00f3pica (DA) se manifiesta a trav\u00e9s de un cuadro polimorfo de eflorescencias, con prurito y xerosis en primer plano. Adem\u00e1s de las terapias con anticuerpos dupilumab, tralokinumab y lebrikizumab, que se dirigen a la v\u00eda de se\u00f1alizaci\u00f3n IL-4\/IL-13, ahora se dispone de un cuarto biol\u00f3gico, el nemolizumab, para el tratamiento de la DA. Este \u00faltimo se dirige al receptor de la IL-31, que media el picor no histamin\u00e9rgico. Los estudios cl\u00ednicos sobre los anticuerpos anti-OX40(L) tambi\u00e9n han arrojado resultados prometedores.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fbiologicos-establecidos-y-novedosos-el-panorama-terapeutico-esta-en-constante-cambio%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Cl\u00ednicamente, la dermatitis at\u00f3pica (DA) se manifiesta a trav\u00e9s de un cuadro polimorfo de eflorescencias, con prurito y xerosis en primer plano. Adem\u00e1s de las terapias con anticuerpos dupilumab, tralokinumab&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fbiologicos-establecidos-y-novedosos-el-panorama-terapeutico-esta-en-constante-cambio%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":550609,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Dermatitis at\u00f3pica de moderada a grave  ","footnotes":""},"category":[11298,11310,11475,11478,11552],"tags":[65573,88956,12425,12531,13573,16249,82423,82421,85934,65669,12522,88957,59241,13309,88958],"powerkit_post_featured":[],"class_list":["post-550608","post","type-post","status-publish","format-standard","has-post-thumbnail","category-alergologia-e-inmunologia-clinica","category-dermatologia-y-venereologia","category-estudios","category-formacion-continua","category-rx-es","tag-adtralza-es","tag-anticuerpo-anti-ox40l","tag-biologicos-es","tag-dermatitis-atopica","tag-dupilumab-es","tag-dupixent-es","tag-ebglyss-es","tag-lebrikizumab-es","tag-nemluvio","tag-nemolizumab-es","tag-picor","tag-receptor-de-il-31","tag-terapia-con-anticuerpos","tag-tralokinumab-es","tag-via-de-senalizacion-il-4-il-13","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-13 12:50:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/550608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=550608"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/550608\/revisions"}],"predecessor-version":[{"id":550610,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/550608\/revisions\/550610"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/550609"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=550608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=550608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=550608"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=550608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}